OUP Management Company’s LENZ Therapeutics LENZ Stock Holding History

OUP Management Company’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.01M	Hold	58,044	–	–	2.27%	5
2023 Q2	$1.06M	Hold	58,044	–	–	1.8%	7
2023 Q1	$995K	Hold	58,044	–	–	1.99%	10
2022 Q4	$1.35M	Hold	58,044	–	–	2.2%	9
2022 Q3	$1.29M	Hold	58,044	–	–	2.01%	11
2022 Q2	$1.12M	Hold	58,044	–	–	1.54%	13
2022 Q1	$2.07M	Hold	58,044	–	–	1.58%	13
2021 Q4	$5.05M	Buy	+58,044	New	+$4.81M	2.28%	11

Other funds holding LENZ

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OUP Management Company's LENZ Position: Q3 2023 in Review

OUP Management Company held its LENZ Therapeutics (LENZ) position steady in Q3 2023 at 58,044 shares worth $1.01M. The position accounts for 2.27% of the portfolio, ranked #5.

OUP Management Company first reported a position in LENZ in Q4 2021 and has held it in 8 quarters since. The position peaked at $5.05M in Q4 2021. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

OUP Management Company held 58,044 shares of LENZ Therapeutics worth $1.01M as of Q3 2023.
OUP Management Company left its LENZ Therapeutics share count unchanged in Q3 2023.
LENZ Therapeutics made up 2.27% of OUP Management Company's portfolio in Q3 2023, its #5 holding.
OUP Management Company first reported a position in LENZ Therapeutics in Q4 2021 and has held it in 8 quarters since.
OUP Management Company's LENZ Therapeutics position peaked at $5.05M in Q4 2021.
67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on OUP Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.